TKT and malignant glioma: In parallel to this, Sandmair et al. (2000) reported on a phase I clinical trial where malignant glioma patients were treated either with replication-defective AdV bearing HSV-tk/GCV or reovirus-mediated HSV-tk/GCV at the tumor resection margin.